Pear Therapeutics: sourced choices
6 product and go-to-market choices, oldest first. Back to the case study
- 2022-12-31Product · Treatment portfolio Three prescription digital treatments addressed distinct diagnosed conditions. PE1
- 2022-12-31Product · Clinician workflow Pear offered a clinician dashboard alongside patient treatment. PE1
- 2022-12-31Product · Fulfillment Reported fulfillment was 53% of prescriptions. PE1
- 2022-12-31Go_To_Market · Payer access Pear pursued payer, provider and government access agreements. PE1
- 2022-12-31Go_To_Market · Paid conversion Payment covered 41% of fulfilled prescriptions in 2022. PE1
- 2023-04-07Go_To_Market · Bankruptcy Chapter 11 filing accompanied workforce reductions and a proposed sale process. PE2